uniQure NV
0EE0.L
$21.02 0.38%
Exchange: LSE | Sector: Healthcare | Industry: Medical Pharmaceuticals
Q1 2025
Published: May 9, 2025

Earnings Highlights

  • Revenue of $1.57M down 81.5% year-over-year
  • EPS of $-0.82 increased by 39.7% from previous year
  • Gross margin of 87.4%
  • Net income of -43.64M
  • "Our strategic focus is achieving milestone results in our clinical trials, as they are crucial for driving revenues in the future." - CEO
0EE0.L
uniQure NV

Executive Summary

In Q1 2025, uniQure NV reported significant revenue challenges with total revenues of $1.567 million, marking an 81.53% year-over-year decline and a staggering 69.99% decline quarter-over-quarter. However, the company maintained a strong gross profit ratio of 87.43%, reflecting effective cost management amidst a pivotal phase of transitioning its clinical pipeline. Their net loss widened to $43.637 million due to increased operational costs, primarily in research and development (R&D) which amounted to $36.14 million.

Despite setbacks in revenue, uniQure continues to invest heavily in advancing its gene therapy portfolio, particularly focusing on its key programs such as Etranacogene dezaparvovec for hemophilia B and AMT-130 for Huntington's disease. Investors should watch the progress of these clinical trials as successful outcomes could revitalize revenue streams in the near future.

Key Performance Indicators

Revenue
Decreasing
1.57M
QoQ: -69.99% | YoY: -81.53%
Gross Profit
Increasing
1.37M
87.43% margin
QoQ: -70.23% | YoY: 140.65%
Operating Income
Increasing
-39.33M
QoQ: 14.18% | YoY: 28.96%
Net Income
Increasing
-43.64M
QoQ: 40.44% | YoY: 33.50%
EPS
Increasing
-0.82
QoQ: 45.70% | YoY: 39.71%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q3 2025 3.70 -1.38 +61.8% View
Q2 2025 5.26 -0.69 -52.7% View
Q1 2025 1.57 -0.82 -81.5% View
Q4 2024 5.22 -1.51 -22.0% View
Q3 2024 2.29 -0.91 +62.5% View